Citations

Institution: Mayo Clinic Clear

Showing 10 of 108162 citations.

“This lifetime commitment”: Public conceptions of disability and noninvasive prenatal genetic screening
Steinbach, Rosemary J. , Allyse, Megan , Michie, Marsha , Liu, Emily Y., Cho, Mildred K. , Allyse, Megan A

American Journal of Medical Genetics Part A | November 14, 2015 | Volume: 170 | Issue: 2 | Pages: 363-374

10.1002/ajmg.a.37459 | PMID 26566970 Get It

Recently, new noninvasive prenatal genetic screening technologies for Down syndrome and other genetic conditions have become commercially available. Unique characteristics of these screening tests have reignited long‐standing concerns about prenatal testing for intellectual and developmental disabilities. We conducted a web‐based survey of a sample of the US public to examine how attitudes towards disability inform views of prenatal testing in the context of these rapidly advancing prenatal genetic screening technologies. Regardless of opinion toward disability, the majority of respondents supported both the availability of screening and the decision to continue a pregnancy positive for aneuploidy. Individuals rationalized their support with various conceptions of disability; complications of the expressivist argument and other concerns from the disability literature were manifested in many responses analyzed. © 2015 Wiley Periodicals, Inc.
Hail to the chief—Keith Lindor, our new AASLD president
Shah, Vijay H. , Gores, G. J., LaRusso, Nick F., Gores, Greg J

Hepatology | November 14, 2015 | Volume: 63 | Issue: 2 | Pages: 357-359

10.1002/hep.28342 | PMID 26566704 Get It

Herpes simplex virus 1 encephalitis associated with voltage-gated calcium channel autoimmunity
Pawate, Siddharama , Lennon, Vanda A. , Bloch, Karen C. , Brown, Kelly M. , Bradshaw, Michael J, Bradshaw, Michael

Neurology | November 14, 2015 | Volume: 85 | Issue: 24 | Pages: 2176-2177

10.1212/wnl.0000000000002218 | PMID 26567268 Get It

Prognostic Value of Flow‐Mediated Vasodilation in Brachial Artery and Fingertip Artery for Cardiovascular Events: A Systematic Review and Meta‐Analysis
Matsuzawa, Yasushi , Kwon, Taek‐Geun , Lennon, Ryan J. , Lerman, Lilach O. , Lerman, Amir

Journal of the American Heart Association | November 14, 2015 | Volume: 4 | Issue: 11 | Pages: No page available

10.1161/jaha.115.002270 | PMID 26567372 Get It

Background Endothelial dysfunction plays a pivotal role in cardiovascular disease progression, and is associated with adverse events. The purpose of this systematic review and meta‐analysis was to investigate the prognostic magnitude of noninvasive peripheral endothelial function tests, brachial artery flow‐mediated dilation (FMD), and reactive hyperemia–‐peripheral arterial tonometry (RH‐PAT) for future cardiovascular events. Methods and Results Databases of MEDLINE, EMBASE, and the Cochrane Library were systematically searched. Clinical studies reporting the predictive value of FMD or RH‐PAT for cardiovascular events were identified. Two authors selected studies and extracted data independently. Pooled effects were calculated as risk ratio (RR) for continuous value of FMD and natural logarithm of RH‐PAT index (Ln_RHI) using random‐effects models. Thirty‐five FMD studies of 17 280 participants and 6 RH‐PAT studies of 1602 participants were included in the meta‐analysis. Both endothelial function tests significantly predicted cardiovascular events (adjusted relative risk [95% CI]: 1% increase in FMD 0.88 [0.84–0.91], P <0.001, 0.1 increase in Ln_RHI 0.79 [0.71–0.87], P <0.001). There was significant heterogeneity in the magnitude of the association across studies. The magnitude of the prognostic value in cardiovascular disease subjects was comparable between these 2 methods; a 1 SD worsening in endothelial function was associated with doubled cardiovascular risk. Conclusions Noninvasive peripheral endothelial function tests, FMD and RH‐PAT, significantly predicted cardiovascular events, with similar prognostic magnitude. Further research is required to determine whether the prognostic values of these 2 methods are independent of each other and whether an endothelial function–guided strategy can provide benefit in improving cardiovascular outcomes.
Clinicopathologic features of IgG/IgA pemphigus in comparison with classic (IgG) and IgA pemphigus
Toosi, Siavash, Collins, Jeffrey W. , Lohse, Christine M. , Wolz, Michael , Wieland, Carilyn N. , Camilleri, Michael , Bruce, Alison J., McEvoy, Marian T., Lehman, Julia S. , Wolz, Michael M, Lehman, Julia S

International Journal of Dermatology | November 14, 2015 | Volume: 55 | Issue: 4 | Pages: No page available

10.1111/ijd.13025 | PMID 26566588 Get It

AbstractBackgroundThe pemphigus group is characterized by the presence of circulating immunoglobulins against desmosomes. IgG/IgA pemphigus is defined by the presence of IgG and IgA cell surface deposits upon direct immunofluorescence (DIF) and/or circulating IgG and IgA autoantibodies upon indirect immunofluorescence. Previous reports of patients with IgG/IgA pemphigus are sparse. Whether IgG/IgA pemphigus is best classified as a subtype of IgG (classic) pemphigus or IgA pemphigus, or as a distinct entity, has yet to be determined.ObjectivesWe compared the features of patients with IgG/IgA pemphigus to those of IgG pemphigus and IgA pemphigus.MethodsRetrospective clinicopathologic study of patients with IgG, IgG/IgA, and IgA pemphigus evaluated at our clinic (1993–2013).ResultsWe included 26, 13, and seven patients with IgG, IgG/IgA, and IgA pemphigus, respectively. Patients with IgG/IgA pemphigus did not differ significantly from patients with IgG pemphigus in terms of clinical and microscopic features, DIF findings, anti‐desmoglein antibody values, and treatments required. However, patients with IgG/IgA pemphigus were significantly different from patients with IgA pemphigus regarding intertriginous distribution (P = 0.038) and pustular lesions (P < 0.001), acantholysis (P = 0.043), and presence of intercellular C3 deposits on DIF (P < 0.001).ConclusionComparative clinicopathologic data imply that IgG/IgA pemphigus may best be regarded as a variant of IgG pemphigus and distinct from IgA pemphigus.
PD-1 Blunts the Function of Ovarian Tumor–Infiltrating Dendritic Cells by Inactivating NF-κB
Karyampudi, Lavakumar, Lamichhane, Purushottam , Krempski, James , Kalli, Kimberly R., Behrens, Marshall D., Vargas, Doris M., Hartmann, Lynn C. , Janco, Jo Marie Tran, Hedin, Karen E. , Dietz, Allan B. , Goode, Ellen L. , Knutson, Keith L. , Janco, Jo Marie T, Dong, Haidong , Knutson, Keith L. , Dietz, Allan B , Krempski, James W

Cancer Research | November 13, 2015 | Volume: 76 | Issue: 2 | Pages: 239-250

10.1158/0008-5472.can-15-0748 | PMID 26567141 Get It

Abstract The PD-1:PD-L1 immune signaling axis mediates suppression of T-cell–dependent tumor immunity. PD-1 expression was recently found to be upregulated on tumor-infiltrating murine (CD11c+CD11b+CD8−CD209a+) and human (CD1c+CD19−) myeloid dendritic cells (TIDC), an innate immune cell type also implicated in immune escape. However, there is little knowledge concerning how PD-1 regulates innate immune cells. In this study, we examined the role of PD-1 in TIDCs derived from mice bearing ovarian tumors. Similar to lymphocytes, TIDC expression of PD-1 was associated with expression of the adapter protein SHP-2, which signals to NF-κB; however, in contrast to its role in lymphocytes, we found that expression of PD-1 in TIDC tonically paralyzed NF-κB activation. Further mechanistic investigations showed that PD-1 blocked NF-κB–dependent cytokine release in a SHP-2–dependent manner. Conversely, inhibition of NF-κB–mediated antigen presentation by PD-1 occurred independently of SHP-2. Collectively, our findings revealed that PD-1 acts in a distinct manner in innate immune cells compared with adaptive immune cells, prompting further investigations of the signaling pathways controlled by this central mediator of immune escape in cancer. Cancer Res; 76(2); 239–50. ©2015 AACR.
Hypereosinophilic syndrome: cardiac diagnosis and management
Mankad, Rekha , Bonnichsen, Crystal R. , Mankad, Sunil , Bonnichsen, Crystal, Mankad, Rekha

Heart | November 13, 2015 | Volume: 102 | Issue: 2 | Pages: 100-106

10.1136/heartjnl-2015-307959 | PMID 26567231 Get It

Hypereosinophilic syndrome (HES) is a heterogeneous group of conditions that is defined at its core by hypereosinophilia (HE) (blood eosinophil count of >1.5×10 9 /L) and organ damage directly attributable to the HE. Cardiac dysfunction occurs frequently in all forms of HES and is a major cause of morbidity and mortality. Once a significantly elevated eosinophil count is identified, it must be confirmed on repeat testing and the aetiology for the HE must be rigorously sought out with a focus on identifying whether organ dysfunction is occurring. Echocardiography is routinely performed to assess for cardiac involvement, looking for evidence of left ventricular and/or right ventricular apical obliteration or thrombi or a restrictive cardiomyopathy. Cardiac magnetic resonance imaging and CT are often useful adjuncts to establish the diagnosis but endomyocardial biopsy remains the gold standard. To decrease the degree of eosinophilia, treatment can include corticosteroids and/or imatinib based on the aetiology. Anticoagulation, standard heart failure therapy for a restrictive cardiomyopathy and finally cardiac transplantation may be indicated in the treatment algorithm.
Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms
Diamond, Eli L. , Durham, Benjamin H. , Haroche, Julien , Yao, Zhan , Ma, Jing , Wang, Zhaoming , Choi, John , Kim, Eun Hee , Cohen‐Aubart, Fleur , Lee, Stanley Chun-Wei , Gao, Yijun , Micol, Jean‐Baptiste , Campbell, Patrick , Walsh, Michael P. , Sylvester, Brooke E., Dolgalev, Igor , Aminova, Olga, Heguy, Adriana , Zappile, Paul, Nakitandwe, Joy , Ganzel, Chezi , Dalton, James , Ellison, David W. , Estrada‐Veras, Juvianee , Lacouture, Mario E. , Gahl, William A. , Stephens, Philip J., Miller, Vincent A. , Ali, Siraj M. , Briggs, Samuel, Fasan, Omotayo , Block, Jared , Héritier, Sébastien , Solit, David B. , Hyman, David M. , Baselga, José , Jankú, Filip , Taylor, Barry S. , Amoura, Zahir , Rosen, Neal , Parikh, Sameer A. , Ross, Jeffrey S , Donadieu, Jean , Park, Christopher Y. , Doǧan, Ahmet , Emile, Jean‐François , Gruber, Tanja Andrea , Abdel‐Wahab, Omar , Diamond, Eli L , Wang, Zhaoming , Héritier, Sébastien , Durham, Benjamin

Cancer Discovery | November 13, 2015 | Volume: 6 | Issue: 2 | Pages: 154-165

10.1158/2159-8290.cd-15-0913 | PMID 26566875 Get It

Abstract Histiocytic neoplasms are clonal, hematopoietic disorders characterized by an accumulation of abnormal, monocyte-derived dendritic cells or macrophages in Langerhans cell histiocytosis (LCH) and non-Langerhans cell histiocytosis (non-LCH), respectively. The discovery of BRAFV600E mutations in approximately 50% of these patients provided the first molecular therapeutic target in histiocytosis. However, recurrent driving mutations in the majority of patients with BRAFV600E–wild-type non-LCH are unknown, and recurrent cooperating mutations in non-MAP kinase pathways are undefined for the histiocytic neoplasms. Through combined whole-exome and transcriptome sequencing, we identified recurrent kinase fusions involving BRAF, ALK, and NTRK1, as well as recurrent, activating MAP2K1 and ARAF mutations in patients with BRAFV600E–wild-type non-LCH. In addition to MAP kinase pathway lesions, recurrently altered genes involving diverse cellular pathways were identified. Treatment of patients with MAP2K1- and ARAF-mutated non-LCH using MEK and RAF inhibitors, respectively, resulted in clinical efficacy, demonstrating the importance of detecting and targeting diverse kinase alterations in these disorders. Significance: We provide the first description of kinase fusions in systemic histiocytic neoplasms and activating ARAF and MAP2K1 mutations in non-Langerhans histiocytic neoplasms. Refractory patients with MAP2K1- and ARAF-mutant histiocytoses had clinical responses to MEK inhibition and sorafenib, respectively, highlighting the importance of comprehensive genomic analysis of these disorders. Cancer Discov; 6(2); 154–65. ©2015 AACR. This article is highlighted in the In This Issue feature, p. 109
Antiviral therapy in management of chronic hepatitis B viral infection in children: A systematic review and meta‐analysis
Jonas, Maureen M. , McMahon, Brian J. , Brown, Robert S., Wong, John B. , Ahmed, Ahmed T. , Farah, Wigdan , Mouchli, Mohamed A., Singh, Siddharth , Murad, M. Hassan , Mohammed, Khaled , Murad, Mohammad Hassan, Lok, Anna S. , Prokop, Larry J. , Murad, M Hassan , Farah, Wigdan

Hepatology | November 13, 2015 | Volume: 63 | Issue: 1 | Pages: 307-318

10.1002/hep.28278 | PMID 26566163 Get It

Most individuals with chronic hepatitis B viral (HBV) infection acquired the infection around the time of birth or during early childhood. We aimed to synthesize evidence regarding the effectiveness of antiviral therapy in the management of chronic HBV infection in children. We conducted a comprehensive search of multiple databases from 1988 to December 2, 2014, for studies that enrolled children (<18 years) with chronic HBV infection treated with antiviral therapy. We included observational studies and randomized controlled trials (RCTs). Two independent reviewers selected studies and extracted data. In the 14 included studies, two cohort studies showed no significant reduction in the already low risk of hepatocellular carcinoma or cirrhosis and 12 RCTs reported intermediate outcomes. In RCTs with posttreatment follow‐up <12 months, antiviral therapy compared to placebo improved alanine aminotransferase normalization (risk ratio [RR] = 2.3, 95% confidence interval [CI] 1.7‐3.2), hepatitis B e antigen (HBeAg) clearance/loss (RR = 2.1, 95% CI 1.5‐3.1), HBV DNA suppression (RR = 2.9, 95% CI 1.8‐4.6), HBeAg seroconversion (RR = 2.1, 95% CI 1.4‐3.3), and hepatitis B surface antigen clearance (RR = 5.8, 95% CI 1.1‐31.5). In RCTs with posttreatment follow‐up ≥12 months, antiviral therapy improved cumulative HBeAg clearance/loss (RR = 1.9, 95% CI 1.7‐3.1), HBeAg seroconversion (RR = 2.1, 95% CI 1.3‐3.5), alanine aminotransferase normalization (RR = 1.4, 95% CI 1.1‐1.7), and HBV DNA suppression (RR = 1.4, 95% CI 1.1‐1.8) but not hepatitis B surface antigen clearance or seroconversion. Conclusion: In children with chronic HBV infection, antivirals compared to no antiviral therapy improve HBV DNA suppression and frequency of alanine aminotransferase normalization and HBeAg seroconversion. (Hepatology 2016;63:307–318)
Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta‐analysis
Brown, Robert S., McMahon, Brian J. , Wong, John B. , Ahmed, Ahmed T. , Mouchli, Mohamed A., Murad, M. Hassan , Mohammed, Khaled , Murad, Mohammad Hassan, Lok, Anna S. , Wang, Zhen , Prokop, Larry J. , Murad, M Hassan

Hepatology | November 13, 2015 | Volume: 63 | Issue: 1 | Pages: 319-333

10.1002/hep.28302 | PMID 26565396 Get It

Perinatal or mother‐to‐child transmission (MTCT) of hepatitis B virus (HBV) remains the major risk factor for chronic HBV infection worldwide. In addition to hepatitis B immune globulin and vaccination, oral antiviral therapies in highly viremic mothers can further decrease MTCT of HBV. We conducted a systematic review and meta‐analysis to synthesize the evidence on the efficacy and maternal and fetal safety of antiviral therapy during pregnancy. A protocol was developed by the American Association for the Study of Liver Diseases guideline writing committee. We searched multiple databases for controlled studies that enrolled pregnant women with chronic HBV infection treated with antiviral therapy. Outcomes of interest were reduction of MTCT and adverse outcomes to mothers and newborns. Study selection and data extraction were done by pairs of independent reviewers. We included 26 studies that enrolled 3622 pregnant women. Antiviral therapy reduced MTCT, as defined by infant hepatitis B surface antigen seropositivity (risk ratio = 0.3, 95% confidence interval 0.2‐0.4) or infant HBV DNA seropositivity (risk ratio = 0.3, 95% confidence interval 0.2‐0.5) at 6‐12 months. No significant differences were found in the congenital malformation rate, prematurity rate, and Apgar scores. Compared to control, lamivudine or telbivudine improved maternal HBV DNA suppression at delivery and during 4‐8 weeks' postpartum follow‐up. Tenofovir showed improvement in HBV DNA suppression at delivery. No significant differences were found in postpartum hemorrhage, cesarean section, and elevated creatinine kinase rates. Conclusions: Antiviral therapy improves HBV suppression and reduces MTCT in women with chronic HBV infection with high viral load compared to the use of hepatitis B immunoglobulin and vaccination alone; the use of telbivudine, lamivudine, and tenofovir appears to be safe in pregnancy with no increased adverse maternal or fetal outcome. (Hepatology 2016;63:319–333)